

Listing of Claims:

1. (Original) An HFA drug formulation comprising a partially or fully acylated alpha (α), beta (β) or gamma (γ) cyclodextrin.
2. (Original) A formulation according to claim 1 in which the HFA is HFA 134a, 227 or a mixture thereof.
3. (Previously Presented) A formulation according to claim 1 in the form of a solution.
4. (Previously Presented) A formulation according to claim 1 in the form of a suspension.
5. (Previously Presented) A formulation according to claim 1 in which the cyclodextrin is acylated with one or more groups selected from Acetyl, Acryloyl, Alanyl, Aminocarbonyl, β -Alanyl, alkyl Azelaoyl, Benzoyl, Butyryl, Caproyl, Crotomoyl, Formyl, alkyl Glutaryl, Glycoloyl, Glycyl, Glyoxyloyl, Heptadecanoyl, Isobutyryl, Isovaleryl, Lactoyl, Levulinoyl, alkyl Malonyl, Mandeloyl, Methacryloyl, Myristoyl, Monanoyl, alkyl Oxanyl, Palmitoyl, alkyl Pimeloyl, Pivaloyl, Propanoyl, Salicyloyl, Seryl, Sorboyl, Stearoyl, alkyl Suberoyl, alkyl Succinoyl, Theronoyl, Valeryl or Valyl.
6. (Previously Presented) A formulation according to claim 1 in which the drug is fluticasone propionate, budesonide, formoterol fumarate dihydrate, salmeterol xinafoate, ciclesonide or mometasone furoate.
7. (Previously Presented) A formulation according to claim 1 in which there are two drugs and these are budesonide and formoterol fumarate dihydrate.
8. (Cancelled)

9. (Cancelled)

10. (Previously Presented) A method of treating a respiratory disease which comprises administering to a patient a therapeutically effective amount of a formulation according to claim 1.

11. (Previously Presented) A formulation according to any one of claims 1 to 5 in which the drug is formoterol fumarate dihydrate.

12. (Previously Presented) A formulation according to any one of claims 1 to 5 in which the drug is budesonide.

13. (Previously Presented) A formulation according to any one of claims 1 to 6 in which there are two drugs and these are fluticasone propionate and salmeterol xinafoate, ciclesonide and formoterol fumarate dihydrate, mometasone furoate and formoterol fumarate dihydrate, or, fluticasone propionate and formoterol fumarate dihydrate.

14. (New) A formulation according to claim 1, wherein the formulation is substantially free of a co-solvent.